

# NHSBT Finance Report


April 2021

Contents	Page
Financial Performance Headlines	2-3
Financial Performance - by Division	4
NHSBT Income and Expenditure Statement	5
Contribution Statement	6
Cash Flow position	7

# 2021/22 Financial Performance Headlines – April 2021


Surplus of £0.8m (£0.9m ahead of plan)

## Blood and Group Net Income & Expenditure (excl. Change Programme)




In line with budget.

## Clinical Services Net Income & Expenditure




Favourable +£0.5m variance – activity higher than plan (predominately TAS and RCI)

## Organ Donation & Transplantation: Net Funding & Expenditure




In line with plan

## Blood and Group Change Programme: Full Year Forecast




Full Year budget is £17m.

## NHSBT Cash Flow 2021/22






Forecast closing cash balance at the end of March 2022 is £27.4m.

## NHSBT Income & Expenditure Full Year Forecast



NHSBT Full Year Budget is an £18.4m deficit (driven by transformation spend)

# 2021/22 NHSBT Financial Performance Headlines – April 2021

<p>Year to date I&amp;E Position</p>	<p>+£0.8m surplus</p>	<p><b>NHSBT I&amp;E position surplus +£0.8m, £0.9m better than plan.</b></p> <ul style="list-style-type: none"> <li>• Blood and Group – in line with plan</li> <li>• Clinical Services +£0.4m – increased activity (predominately TAS &amp; RCI)</li> <li>• ODT – in line with plan</li> <li>• TES +£0.3m – increased sales activity (predominately Ocular)</li> </ul>	
<p>Full year forecast</p>	<p>-£18.4m deficit</p>	<p><b>Budget deficit of £18.4m, driven by planned transformation expenditure</b></p> <ul style="list-style-type: none"> <li>• First formal forecast will be provided at Quarter 1</li> </ul>	
<p>Cash and Debtors</p>	<p>Cash balance £50m</p>	<p><b>Debtor days finished at 11 days - 11 days ahead of target</b></p> <p><b>90+ overdue remains at £0.4m (£0.1m ahead of target)</b></p> <p><b>Closing cash balance at the end of April 2021 is £50m. Cash forecast of £27m at the end of March 2022.</b></p>	

The existing pages of the old Board performance report will continue to be reported through Q1 pending a refresh of the structure and content (for the June / Q1 report).

Work on strategy and plans continues. Subject to this, the current trajectory (effectively a “do nothing” scenario) is suggesting a 5.6% price increase would be needed for Blood in 2022/23.

DHSC have requested a short turn around submission in cost saving opportunities (by 2024/25) in advance of the formal SR21 process. In respect of NHSBT, this applies to the programme funding received for ODT and Stem Cells. An update will be provided to the May Board meeting.

# Financial Performance by Division – Year to Date April 2021 (full I&E statement follows)

Surplus of £0.8m (+£0.9m ahead of plan)

Blood Supply	April (APM01)		
	Bud.	Act.	Var.
(£)m			
Income	24.5	24.8	0.2
CVP Funding	0.0	4.4	4.4
Expenditure	(14.0)	(14.7)	(0.7)
CVP Expenditure	0.0	(4.4)	(4.4)
<b>Surplus/(Deficit)</b>	<b>10.6</b>	<b>10.1</b>	<b>(0.4)</b>

Demand is higher than plan for blood components (£0.1m) and non-clinical issues (£0.1m).

This is offset by increased operating expenditure across all directorates (Blood Donation, Manufacturing and Logistics) driven by increased headcount, agency and venue hire. This will be monitored and any adverse persistent trends reported in the Q1 re-forecast.

Group Services	April (APM01)		
	Bud.	Act.	Var.
(£)m			
Income	1.3	1.4	0.1
Expenditure	(13.6)	(13.2)	0.4
Blood and Group Transformation	(0.5)	(0.5)	0.0
<b>Surplus/(Deficit)</b>	<b>(12.9)</b>	<b>(12.4)</b>	<b>0.5</b>

Group Services are reporting small favourable variances across the majority of directorates.

<b>Blood and Group Surplus/(Deficit)</b>	<b>(2.3)</b>	<b>(2.2)</b>	<b>0.1</b>
--	--------------	--------------	------------

Clinical Services	April (APM01)		
	Bud.	Act.	Var.
(£)m			
Income	5.4	5.6	0.2
Expenditure	(4.9)	(4.7)	0.2
Change Programme	(0.1)	(0.1)	0.0
<b>Surplus/(Deficit)</b>	<b>0.4</b>	<b>0.9</b>	<b>0.4</b>

Activity is higher than plan – especially in TAS and RCI.

Organ Donation & Transplantation	April (APM01)		
	Bud.	Act.	Var.
(£)m			
Income	7.0	6.7	(0.3)
Expenditure	(5.5)	(5.1)	0.4
Change Programme	0.2	0.2	0.0
<b>Surplus/(Deficit)</b>	<b>1.7</b>	<b>1.8</b>	<b>0.1</b>

DHSC funding is lower than budget. We are checking that costs transferred into group services, as part of the Operating Model changes (primarily IT costs) have not been excluded from the funding requirement.

The transformation plan (£5m) agreed with DHSC is funded through cash reserves brought forward from 2020/21.

Tissues and Eye Services	April (APM01)		
	Bud.	Act.	Var.
(£)m			
Income	1.1	1.3	0.2
Expenditure	(1.0)	(0.9)	0.1
<b>Surplus/(Deficit)</b>	<b>0.1</b>	<b>0.4</b>	<b>0.3</b>

Activity is higher than (a conservative) plan – with hospitals increasing elective surgery.

<b>NHSBT Total</b>	<b>(0.1)</b>	<b>0.8</b>	<b>0.9</b>
--------------------	--------------	------------	------------

Period				Year to date			Full year	
Budget	Actual	Variance		Budget	Actual	Variance	2020-21 Actual	Budget
£k	£k	£k		£k	£k	£k	£k	£k
0	4,350	4,350	<b>Blood and Group</b>	0	4,350	4,350	57,623	0
883	883	0	Programme Funding - Convalescent Plasma	883	883	0	11,061	10,600
24,282	24,505	223	Programme Funding - Corporate	24,282	24,505	223	280,280	291,747
263	279	16	Blood & Components Income	263	279	16	3,165	3,313
186	215	29	Blood Supply Other Income	186	215	29	2,000	2,377
87	92	5	Clinical Services - Research & Development	87	92	5	1,221	1,042
134	177	42	Clinical Services Income - Medical	134	177	42	3,385	1,652
<b>25,836</b>	<b>30,501</b>	<b>4,666</b>	Group Services Other Income	<b>25,836</b>	<b>30,501</b>	<b>4,666</b>	<b>358,735</b>	<b>310,731</b>
(1,104)	(804)	301	<b>Blood and Group Income</b>	(1,104)	(804)	301	(515)	0
(22)	(4,372)	(4,350)	Cost of Sales - Blood Component Stock Movement	(22)	(4,372)	(4,350)	(57,623)	(22)
(5,883)	(6,319)	(436)	Convalescent Plasma	(5,883)	(6,319)	(436)	(66,820)	(70,814)
(5,364)	(5,571)	(208)	Blood Supply: Blood Donation	(5,364)	(5,571)	(208)	(63,248)	(66,131)
(1,625)	(1,970)	(346)	Blood Supply: Manufacturing, Testing & Issue	(1,625)	(1,970)	(346)	(20,293)	(19,693)
(65)	(52)	13	Blood Supply: Logistics	(65)	(52)	13	(644)	(780)
(1,415)	(1,348)	67	Chief Executive and Board	(1,415)	(1,348)	67	(18,252)	(20,369)
(505)	(459)	47	Donor Experience	(505)	(459)	47	(5,378)	(6,166)
(3,574)	(3,500)	75	Quality	(3,574)	(3,500)	75	(45,278)	(44,767)
(522)	(536)	(14)	Estates & Facilities	(522)	(536)	(14)	(6,012)	(6,271)
(307)	(311)	(4)	Finance	(307)	(311)	(4)	(3,088)	(3,696)
(176)	(120)	57	Strategy and Transformation	(176)	(120)	57	(1,675)	(2,123)
(825)	(862)	(37)	Business Transformation Services	(825)	(862)	(37)	(9,510)	(10,112)
(3,066)	(2,879)	187	People	(3,066)	(2,879)	187	(34,923)	(39,879)
(541)	(541)	0	Digital, Data and Technology Services	(541)	(541)	0	(12,701)	(16,999)
(391)	(402)	(10)	Change Programme	(391)	(402)	(10)	(4,835)	(5,346)
(1,399)	(1,363)	36	Clinical Services: Research & Development	(1,399)	(1,363)	36	(15,417)	(16,692)
(1,387)	(1,358)	30	Clinical Services: Medical	(1,387)	(1,358)	30	(32,073)	(15,325)
<b>(28,171)</b>	<b>(32,765)</b>	<b>(4,593)</b>	Miscellaneous and Capital Charges	<b>(28,171)</b>	<b>(32,765)</b>	<b>(4,593)</b>	<b>(398,287)</b>	<b>(345,183)</b>
<b>(2,335)</b>	<b>(2,263)</b>	<b>72</b>	<b>Blood and Group Expenditure</b>	<b>(2,335)</b>	<b>(2,263)</b>	<b>72</b>	<b>(39,552)</b>	<b>(34,452)</b>
			<b>Blood and Group Total</b>					
			<b>Clinical Services (DTAS)</b>					
455	455	0	Programme Funding - Diagnostics, Therapeutic Apheresis & Stem Cells	455	455	0	4,173	5,462
4,934	5,117	183	Diagnostic and Therapeutic Services Income	4,934	5,117	183	58,608	66,747
<b>5,389</b>	<b>5,572</b>	<b>183</b>	<b>Clinical Services Income</b>	<b>5,389</b>	<b>5,572</b>	<b>183</b>	<b>62,781</b>	<b>72,209</b>
(4,893)	(4,653)	240	Clinical Services: Diagnostics, Therapeutic Apheresis and Stem Cells	(4,893)	(4,653)	240	(53,645)	(60,618)
(60)	(58)	1	Clinical Services: Diagnostics, Therapeutic Apheresis and Stem Cells Change Programme	(60)	(58)	1	(903)	(3,740)
<b>(4,953)</b>	<b>(4,712)</b>	<b>241</b>	<b>Clinical Services Expenditure</b>	<b>(4,953)</b>	<b>(4,712)</b>	<b>241</b>	<b>(54,548)</b>	<b>(64,358)</b>
<b>436</b>	<b>860</b>	<b>424</b>	<b>Clinical Services Total</b>	<b>436</b>	<b>860</b>	<b>424</b>	<b>8,233</b>	<b>7,850</b>
			<b>Organ Donation &amp; Transplantation</b>					
5,970	5,717	(254)	Programme Funding - Organ Donation & Transplantation	5,970	5,717	(254)	62,327	71,643
54	34	(20)	Programme Funding - Organ Donation and Transplantation - Opt Out	54	34	(20)	12,091	650
278	329	52	Organ Donation & Transplantation - NHSE Income	278	329	52	1,617	3,333
994	994	0	Organ Donation & Transplantation - UKHDs & Other Income	994	994	0	11,971	11,930
<b>7,296</b>	<b>7,074</b>	<b>(222)</b>	<b>ODT Income</b>	<b>7,296</b>	<b>7,074</b>	<b>(222)</b>	<b>88,006</b>	<b>87,557</b>
(5,462)	(5,110)	353	OTDT - Organ Donation and Transplantation	(5,462)	(5,110)	353	(55,260)	(66,167)
(165)	(150)	16	OTDT - Organ Donation and Transplantation Change Programme	(165)	(150)	16	(14,860)	(15,302)
<b>(5,628)</b>	<b>(5,259)</b>	<b>368</b>	<b>ODT Expenditure</b>	<b>(5,628)</b>	<b>(5,259)</b>	<b>368</b>	<b>(70,120)</b>	<b>(81,469)</b>
<b>1,669</b>	<b>1,815</b>	<b>146</b>	<b>ODT Total</b>	<b>1,669</b>	<b>1,815</b>	<b>146</b>	<b>17,886</b>	<b>6,088</b>
			<b>Tissues and Eye Services</b>					
1,064	1,250	187	Tissue & Eye Services Income	1,064	1,250	187	11,994	14,298
42	42	0	Programme Funding - Tissues & Eye Services	42	42	0	0	500
<b>1,105</b>	<b>1,292</b>	<b>187</b>	<b>TES Income</b>	<b>1,105</b>	<b>1,292</b>	<b>187</b>	<b>11,994</b>	<b>14,798</b>
(63)	(53)	9	Cost of Sales - Tissues Stock Movement	(63)	(53)	9	(727)	(750)
(976)	(869)	107	OTDT - Tissue and Eye Services	(976)	(869)	107	(10,850)	(11,967)
<b>(1,039)</b>	<b>(923)</b>	<b>116</b>	<b>TES Expenditure</b>	<b>(1,039)</b>	<b>(923)</b>	<b>116</b>	<b>(11,577)</b>	<b>(12,717)</b>
<b>67</b>	<b>370</b>	<b>303</b>	<b>TES Total</b>	<b>67</b>	<b>370</b>	<b>303</b>	<b>417</b>	<b>2,080</b>
			<b>NHSBT Summary</b>					
<b>39,627</b>	<b>44,440</b>	<b>4,813</b>	<b>Income</b>	<b>39,627</b>	<b>44,440</b>	<b>4,813</b>	<b>521,516</b>	<b>485,294</b>
<b>(39,791)</b>	<b>(43,658)</b>	<b>(3,868)</b>	<b>Expenditure</b>	<b>(39,791)</b>	<b>(43,658)</b>	<b>(3,868)</b>	<b>(534,532)</b>	<b>(503,728)</b>
<b>(164)</b>	<b>782</b>	<b>946</b>	<b>NHSBT Surplus/(Deficit)</b>	<b>(164)</b>	<b>782</b>	<b>946</b>	<b>(13,016)</b>	<b>(18,434)</b>

# Contribution Statement – Year to Date April 2021

Year to date Actual £m	Blood & Components inc. R&D	Diagnostics		Stem Cells			TAS	TES	ODT	TOTAL
		RCI	H&I	CMT	CBC	SCDT				
<b>Income</b>										
Prices	24.8	1.7	1.0	0.9	-	0.2	1.0	1.3	-	30.9
Central Funding from DHAs	-	-	-	-	-	-	-	-	1.0	1.0
Grant in Aid	5.2	-	-	-	-	0.5	-	0.0	5.8	11.5
Other	0.5	0.1	0.0	0.1	0.0	-	(0.0)	-	0.3	1.1
<b>Total Income</b>	<b>30.5</b>	<b>1.7</b>	<b>1.0</b>	<b>1.0</b>	<b>0.0</b>	<b>0.7</b>	<b>1.0</b>	<b>1.3</b>	<b>7.1</b>	<b>44.4</b>
<b>Expenditure</b>										
Variable Costs										
Consumables	(2.5)	(0.2)	(0.3)	(0.1)	(0.1)	(0.1)	(0.3)	(0.2)	(0.3)	(3.9)
Other	-	-	-	-	-	-	-	-	-	-
<b>Total Variable Costs</b>	<b>(2.5)</b>	<b>(0.2)</b>	<b>(0.3)</b>	<b>(0.1)</b>	<b>(0.1)</b>	<b>(0.1)</b>	<b>(0.3)</b>	<b>(0.2)</b>	<b>(0.3)</b>	<b>(3.9)</b>
<b>Variable Contribution</b>	<b>28.0</b>	<b>1.6</b>	<b>0.8</b>	<b>0.9</b>	<b>(0.0)</b>	<b>0.6</b>	<b>0.8</b>	<b>1.1</b>	<b>6.8</b>	<b>40.5</b>
Direct Costs										
Cost of Sales	(0.8)	-	-	-	-	-	-	(0.1)	-	(0.9)
Pay	(10.2)	(0.8)	(0.6)	(0.4)	(0.1)	(0.2)	(0.4)	(0.6)	(2.6)	(15.9)
Non Pay	(5.1)	(0.0)	(0.0)	(0.1)	(0.0)	(0.1)	(0.1)	(0.2)	(2.5)	(8.1)
<b>Total Direct Costs</b>	<b>(16.1)</b>	<b>(0.8)</b>	<b>(0.6)</b>	<b>(0.5)</b>	<b>(0.2)</b>	<b>(0.3)</b>	<b>(0.5)</b>	<b>(0.8)</b>	<b>(5.1)</b>	<b>(24.9)</b>
<b>Direct Contribution</b>	<b>11.9</b>	<b>0.8</b>	<b>0.2</b>	<b>0.4</b>	<b>(0.2)</b>	<b>0.3</b>	<b>0.3</b>	<b>0.3</b>	<b>1.7</b>	<b>15.6</b>
Direct Support										
Operational Directorate costs	(1.4)	(0.2)	(0.1)	(0.1)	(0.0)	(0.0)	(0.0)	(0.1)	(0.2)	(2.1)
Logistics	(1.6)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(1.6)
Clinical	(0.8)	(0.0)	-	(0.0)	-	(0.0)	(0.0)	(0.0)	(0.1)	(1.0)
Attributable Estates costs	(1.9)	(0.1)	(0.1)	(0.1)	(0.0)	(0.0)	(0.0)	(0.1)	(0.1)	(2.4)
Attributable IT costs	(1.7)	(0.1)	(0.1)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.4)	(2.3)
Depreciation / Cost of Capital	(0.1)	(0.1)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.4)
<b>Total Direct Support</b>	<b>(7.5)</b>	<b>(0.6)</b>	<b>(0.2)</b>	<b>(0.3)</b>	<b>(0.0)</b>	<b>(0.1)</b>	<b>(0.1)</b>	<b>(0.3)</b>	<b>(0.8)</b>	<b>(9.8)</b>
Notional Internal Income Uplift	(0.2)	0.0	0.2	0.0	(0.0)	(0.0)	-	0.0	(0.0)	0.0
<b>Contribution to Unallocated Costs</b>	<b>4.3</b>	<b>0.3</b>	<b>0.1</b>	<b>0.1</b>	<b>(0.2)</b>	<b>0.1</b>	<b>0.2</b>	<b>0.0</b>	<b>0.9</b>	<b>5.8</b>
<b>Total Allocated Costs</b>	<b>(26.3)</b>	<b>(1.5)</b>	<b>(0.9)</b>	<b>(0.9)</b>	<b>(0.3)</b>	<b>(0.6)</b>	<b>(0.8)</b>	<b>(1.3)</b>	<b>(6.2)</b>	<b>(38.6)</b>
Unallocated Costs Apportioned										
Directorate costs	(1.9)	(0.2)	(0.1)	(0.1)	(0.0)	(0.1)	(0.1)	(0.1)	(0.7)	(3.4)
Estates costs	(0.4)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.2)	(0.8)
Depreciation / Cost of Capital	(0.1)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.2)
<b>Total Unallocated Costs</b>	<b>(2.5)</b>	<b>(0.2)</b>	<b>(0.1)</b>	<b>(0.1)</b>	<b>(0.0)</b>	<b>(0.1)</b>	<b>(0.1)</b>	<b>(0.2)</b>	<b>(0.9)</b>	<b>(4.3)</b>
<b>Operating Net Surplus / (Deficit)</b>	<b>1.8</b>	<b>0.1</b>	<b>(0.0)</b>	<b>(0.0)</b>	<b>(0.3)</b>	<b>0.1</b>	<b>0.1</b>	<b>(0.1)</b>	<b>0.0</b>	<b>1.5</b>
Transformation Costs	(0.5)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-	(0.1)	(0.7)
<b>Total Allocated Costs Inc Transformation</b>	<b>(26.8)</b>	<b>(1.5)</b>	<b>(0.9)</b>	<b>(0.9)</b>	<b>(0.3)</b>	<b>(0.6)</b>	<b>(0.8)</b>	<b>(1.3)</b>	<b>(6.3)</b>	<b>(39.4)</b>
<b>Net Surplus / (Deficit) Inc Transformation</b>	<b>1.2</b>	<b>0.0</b>	<b>(0.0)</b>	<b>(0.0)</b>	<b>(0.3)</b>	<b>0.0</b>	<b>0.1</b>	<b>(0.1)</b>	<b>(0.1)</b>	<b>0.8</b>
<b>Budget (YTD)</b>	<b>1.0</b>	<b>(0.1)</b>	<b>0.0</b>	<b>(0.1)</b>	<b>(0.3)</b>	<b>0.0</b>	<b>(0.1)</b>	<b>(0.4)</b>	<b>(0.2)</b>	<b>(0.1)</b>
<b>Variance</b>	<b>0.3</b>	<b>0.1</b>	<b>(0.1)</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.2</b>	<b>0.3</b>	<b>0.0</b>	<b>0.9</b>
<b>RAG STATUS (Actuals V Plan)</b>	<b>G</b>	<b>G</b>	<b>A</b>	<b>G</b>	<b>G</b>	<b>G</b>	<b>G</b>	<b>G</b>	<b>G</b>	<b>G</b>

**Notes:**

1. DTS Management costs (incl Transformation) allocated prorata across Clinical Services Operating unit using allocated costs as a basis.
2. IBGRL & Reagents now included in RCI
3. SCDT includes BBMR & CBB

# Cash Flow – as at April 2021

	Actual Apr-21 £k	Forecast May-21 £k	Forecast Jun-21 £k	Forecast Jul-21 £k	Forecast Aug-21 £k	Forecast Sep-21 £k	Forecast Oct-21 £k	Forecast Nov-21 £k	Forecast Dec-21 £k	Forecast Jan-22 £k	Forecast Feb-22 £k	Forecast Mar-22 £k	Total £k
<b>Opening bank balance</b>	53,211	49,942	49,550	63,435	65,537	67,029	66,575	73,071	72,733	64,990	65,316	52,166	53,211
<b>Receipts</b>													
Debtors & Other Receipts	33,878	33,557	36,247	34,102	29,804	35,530	38,401	33,893	33,359	35,192	33,545	39,582	417,089
Revenue Cash Limit	0	0	17,651	5,884	5,884	5,884	5,884	5,884	5,884	5,884	5,884	5,884	70,605
Revenue Cash Limit - Pensions Uplift	824	0	0	3,296	824	824	824	824	824	824	824	1,536	11,424
Capital Cash Limit	0	0	0	0	0	6,000	0	0	5,000	0	2,000	9,500	22,500
<b>Total Receipts</b>	<b>34,702</b>	<b>33,557</b>	<b>53,898</b>	<b>43,282</b>	<b>36,512</b>	<b>48,237</b>	<b>45,109</b>	<b>40,600</b>	<b>45,067</b>	<b>41,899</b>	<b>42,253</b>	<b>56,502</b>	<b>521,618</b>
<b>Payments</b>													
Staff Expenses	15,253	19,483	19,711	20,669	19,918	20,217	20,362	21,381	22,810	20,375	20,862	27,742	248,782
Other Revenue Payments	22,286	14,065	19,802	20,011	14,501	17,591	17,350	18,557	28,500	19,199	20,357	43,567	255,788
Capital Charges Less DH Credit Due	0	0	0	0	0	10,184	0	0	0	0	10,184	0	20,368
Capital Payments	432	400	500	500	600	700	900	1,000	1,500	2,000	4,000	9,968	22,500
<b>Total Payments</b>	<b>37,971</b>	<b>33,949</b>	<b>40,013</b>	<b>41,180</b>	<b>35,019</b>	<b>48,692</b>	<b>38,612</b>	<b>40,939</b>	<b>52,810</b>	<b>41,574</b>	<b>55,402</b>	<b>81,277</b>	<b>547,438</b>
<b>Closing bank balance</b>	<b>49,942</b>	<b>49,550</b>	<b>63,435</b>	<b>65,537</b>	<b>67,029</b>	<b>66,575</b>	<b>73,071</b>	<b>72,733</b>	<b>64,990</b>	<b>65,316</b>	<b>52,166</b>	<b>27,390</b>	<b>27,390</b>

<b>Debtor Days (Target is 22 days)</b>	11
<b>YTD BPPC By Value % (Target is 95%)</b>	92.2%
<b>YTD BPPC By Number % (Target is 95%)</b>	94.3%

Overdue Debtors NBS/ODT £000's	1-30 Days overdue £000's	31-60 Days overdue £000's	61-90 Days overdue £000's	>90 Days overdue £000's	Total Overdue £000's
<b>Total Overdue Debtors</b>	<b>3,003</b>	<b>813</b>	<b>270</b>	<b>369</b>	<b>4,454</b>

<b>Notional Cash Split</b>	
Blood	£13.7m
Clinical Services	£4.7m
ODT	£9.0m

Top 5 > 90 days Overdue Debtors £000's	Mar-21		Apr-21	
	>90 Days overdue £000's	Total Overdue £000's	>90 Days overdue £000's	Total Overdue £000's
LEEDS TEACHING HOSPITALS NHS TRUST	97	165	83	395
GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUN	63	137	65	219
KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST	14	32	31	588
GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST	15	106	23	253
LIVERPOOL UNIVERSITY HOSPITALS NHS FOUNDATION TRUST			16	173
IMPERIAL COLLEGE HEALTHCARE NHS TRUST	29	57		
<b>Total 5 Overdue Debtors</b>	<b>217</b>	<b>497</b>	<b>218</b>	<b>1,628</b>
Other Debtors	138	3,944	151	2,826
<b>Total Overdue Debtors</b>	<b>335</b>	<b>3,943</b>	<b>369</b>	<b>4,454</b>

>90 DAYS OVERDUE	Profile by Month											
	Actual Apr-21 £000s	Actual May-21 £000s	Actual Jun-21 £000s	Actual Jul-21 £000s	Actual Aug-21 £000s	Actual Sep-21 £000s	Actual Oct-21 £000s	Actual Nov-21 £000s	Actual Dec-21 £000s	Actual Jan-22 £000s	Actual Feb-22 £000s	Actual Mar-22 £000s
Target £0.5m for over 90 days by 30 Apr 2021	369											
Ledger Balance at month end	369											
Target	500											